Aleniglipron
GSBR-1290
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 58
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Arm 1: Participants will receive aleniglipron administered orally | n/r | n/r | n/r | n/r |
| Arm 2: Participants will receive a placebo administered orally | n/r | n/r | n/r | n/r |
Not shown
- Arm 1: Participants will receive aleniglipron administered orally: endpoint not reported
- Arm 2: Participants will receive a placebo administered orally: endpoint not reported